Skip to main content

Table 2 Therapeutic, angiographic, and procedural characteristics of the study population

From: Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

  Total population (n = 2247) Lower GA (≤ 14.4%, n = 1133) Higher GA (> 14.4%, n = 1114) P value
Medication at admission, n (%)
 ACEI/ARB 500 (22.3) 246 (21.7) 254 (22.8) 0.535
 DAPT 677 (30.1) 348 (30.7) 329 (29.5) 0.542
 Aspirin 1192 (53.0) 598 (52.8) 594 (53.3) 0.797
 P2Y12 inhibitors 718 (32.0) 371 (32.7) 347 (31.1) 0.417
 β-Blocker 496 (22.1) 251 (22.2) 245 (22.0) 0.927
 Statins 691 (30.8) 370 (32.7) 321 (28.8) 0.048
 OHA 400 (17.8) 56 (4.9) 344 (30.9)  < 0.001
 Insulin 218 (9.7) 13 (1.1) 205 (18.4)  < 0.001
Medication at discharge, n (%)
 ACEI/ARB 1558 (69.3) 758 (66.9) 800 (71.8) 0.012
 DAPT 2245 (99.9) 1133(100.0) 1112 (99.8) 0.154
 Aspirin 2246 (100.0) 1133 (100.0) 1113(99.9) 0.313
 P2Y12 inhibitors 2247 (100.0) 1133 (100.0) 1114 (100.0)
 β-Blocker 2045 (91.0) 1024 (90.4) 1021 (91.7) 0.292
 Statins 2195 (97.7) 1101 (97.2) 1094 (98.2) 0.105
 OHA 396 (17.6) 56 (4.9) 340 (30.5)  < 0.001
 Insulin 211 (9.4) 12 (1.1) 199 (17.9)  < 0.001
Angiographic data, n (%)
 LM lesion 102 (4.5) 45 (4.0) 57 (5.1) 0.192
 Multi-vessel lesion 1498 (66.7) 655 (57.8) 843 (75.7) < 0.001
 In-stent restenosis 124 (5.5) 47 (4.1) 77 (6.9) 0.004
 Chronic total occlusion lesion 295 (13.1) 136 (12.0) 159 (14.3) 0.111
 SYNTAX score 11.0 ± 5.4 10.0 ± 5.1 12.0 ± 5.5 < 0.001
Procedural information
 Target vessel territory, n (%)
  LM 60 (2.7) 31 (2.7) 29 (2.6) 0.845
  LAD 1464 (65.2) 738 (65.1) 726 (65.2) 0.987
  LCX 784 (34.9) 364 (32.1) 420 (37.7) 0.006
  RCA 952 (42.4) 434 (38.3) 518 (46.5) < 0.001
  Complete revascularization, n (%) 1323 (58.9) 746 (65.8) 577 (51.8) < 0.001
  Number of DES 2.0 ± 1.3 1.9 ± 1.3 2.0 ± 1.3 0.022
  1. GA glycated albumin, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, DAPT dual antiplatelet therapy, OHA oral hypoglycemic agents, LM left main artery, SYNTAX synergy between PCI with taxus and cardiac surgery LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent